Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this safety/mechanistic study is to determine the safety and
tolerability of oral Cellcept when compared with weekly intramuscular Avonex in relapsing
multiple sclerosis. Safety will be assessed by virtue of changes in size and number of
lesions on MRI scans.